TY - JOUR
T1 - Efficacy and safety of rituximab treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitides: Results from a German registry (GRAID)
AU - Roll, Petra
AU - Ostermeier, Eva
AU - Haubitz, Marion
AU - Lovric, Svjetlana
AU - Unger, Leonore
AU - Holle, Julia
AU - Kötter, Ina
AU - Henes, Jörg C.
AU - Bergner, Raoul
AU - Rubbert-Roth, Andrea
AU - Specker, Christof
AU - Schulze-Koops, Hendrik
AU - Müller-Ladner, Ulf
AU - Fleck, Martin
AU - Burmester, Gerd Rüdiger
AU - Hiepe, Falk
AU - Heitmann, Stefan
AU - Aringer, Martin
AU - Fischer-Betz, Rebecca
AU - Dörner, Thomas
AU - Tony, Hans Peter
PY - 2012/11/1
Y1 - 2012/11/1
N2 - Objective. Rituximab (RTX) therapy is a treatment option in patients with refractory antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). We investigated the tolerability and clinical efficacy of RTX in a cohort of patients with refractory AAV. Methods. Clinical and safety data of patients with AAV treated with RTX were retrospectively assessed from the data of a German national registry. Results. In total, 58 patients were included in this analysis (50/58 with granulomatosis with poly-angiitis; 8/58 with microscopic polyangiitis who received at least 1 cycle, 17 patients who received 2 cycles, and 3 patients who received 3 cycles of RTX). Response was classified as complete and partial in 22 (40%) and in 29 cases (52.7%), respectively. Four patients (7.3%) were classified as nonresponders. Conclusion. RTX was well tolerated with good clinical efficacy in patients with refractory AAV. The Journal of Rheumatology
AB - Objective. Rituximab (RTX) therapy is a treatment option in patients with refractory antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). We investigated the tolerability and clinical efficacy of RTX in a cohort of patients with refractory AAV. Methods. Clinical and safety data of patients with AAV treated with RTX were retrospectively assessed from the data of a German national registry. Results. In total, 58 patients were included in this analysis (50/58 with granulomatosis with poly-angiitis; 8/58 with microscopic polyangiitis who received at least 1 cycle, 17 patients who received 2 cycles, and 3 patients who received 3 cycles of RTX). Response was classified as complete and partial in 22 (40%) and in 29 cases (52.7%), respectively. Four patients (7.3%) were classified as nonresponders. Conclusion. RTX was well tolerated with good clinical efficacy in patients with refractory AAV. The Journal of Rheumatology
UR - http://www.scopus.com/inward/record.url?scp=84868382114&partnerID=8YFLogxK
U2 - 10.3899/jrheum.120482
DO - 10.3899/jrheum.120482
M3 - Journal articles
C2 - 22984269
AN - SCOPUS:84868382114
SN - 0315-162X
VL - 39
SP - 2153
EP - 2156
JO - Journal of Rheumatology
JF - Journal of Rheumatology
IS - 11
ER -
